Using Drosophila models of Huntington's disease as a translatable tool

Journal of Neuroscience Methods

Volumn 265, Issue , 2016, Pages 89-98

  Lewis, Elizabeth A ^a   Smith, Gaynor A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Candidate genes; Drosophila; Genetics; Huntington's disease; Screening

Indexed keywords

HUNTINGTIN; HTT PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOENGINEERING; FRUIT FLY MODEL; GENOME-WIDE ASSOCIATION STUDY; HUNTINGTON CHOREA; IN VIVO STUDY; LIFESPAN; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; ANIMAL; DISEASE MODEL; DROSOPHILA; GENETICS; HUMAN; METABOLISM; TRANSGENIC ANIMAL; TRANSLATIONAL RESEARCH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; DROSOPHILA; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84939142675     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2015.07.026     Document Type: Article

References (115)

1. Al-Ramahi I., Lam Y.C., Chen H.K., de Gouyon B., Zhang M., Perez A.M., et al. CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem 2006, 281:26714-26724.
2. Arning L., Kraus P.H., Valentin S., Saft C., Andrich J., Epplen J.T. NR2A, NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics 2005, 6:25-28.
3. Arning L., Monte D., Hansen W., Wieczorek S., Jagiello P., Akkad D.A., et al. ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease. J Mol Med (Berl) 2008, 86:485-490.
4. Barkley D.S., Hardiwidjaja S., Menkes J.H. Abnormalities in growth of skin fibroblasts of patients with Huntington's disease. Ann Neurol 1977, 1:426-430.
5. Bayram-Weston Z., Jones L., Dunnett S.B., Brooks S.P. Light and electron microscopic characterization of the evolution of cellular pathology in HdhQ92 Huntington's disease knock-in mice. Brain Res Bull 2012, 88:171-181.
6. Bayram-Weston Z., Jones L., Dunnett S.B., Brooks S.P. Light and electron microscopic characterization of the evolution of cellular pathology in the R6/1 Huntington's disease transgenic mice. Brain Res Bull 2012, 88:104-112.
7. Bayram-Weston Z., Jones L., Dunnett S.B., Brooks S.P. Light and electron microscopic characterization of the evolution of cellular pathology in YAC128 Huntington's disease transgenic mice. Brain Res Bull 2012, 88:137-147.
8. Bayram-Weston Z., Torres E.M., Jones L., Dunnett S.B., Brooks S.P. Light and electron microscopic characterization of the evolution of cellular pathology in the Hdh(CAG)150 Huntington's disease knock-in mouse. Brain Res Bull 2012, 88:189-198.
9. Besson M.T., Dupont P., Fridell Y.W., Lievens J.C. Increased energy metabolism rescues glia-induced pathology in a Drosophila model of Huntington's disease. Hum Mol Genet 2010, 19:3372-3382.
10. Besson M.T., Alegria K., Garrido-Gerter P., Barros L.F., Lievens J.C. Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD Drosophila model. PLoS ONE 2015, 10:e0118765.
11. Bhutani S., Das A., Maheshwari M., Lakhotia S.C., Jana N.R. Dysregulation of core components of SCF complex in poly-glutamine disorders. Cell Death Dis 2012, 3:e428.
12. Brooks S., Higgs G., Jones L., Dunnett S.B. Longitudinal analysis of the behavioural phenotype in Hdh(CAG)150 Huntington's disease knock-in mice. Brain Res Bull 2012, 88:182-188.
13. Brooks S.P., Janghra N., Workman V.L., Bayram-Weston Z., Jones L., Dunnett S.B. Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice. Brain Res Bull 2012, 88:94-103.
14. Brooks S.P., Jones L., Dunnett S.B. Comparative analysis of pathology and behavioural phenotypes in mouse models of Huntington's disease. Brain Res Bull 2012, 88:81-93.
15. Campesan S., Green E.W., Breda C., Sathyasaikumar K.V., Muchowski P.J., Schwarcz R., et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol 2011, 21:961-966.
16. Carmichael J., Sugars K.L., Bao Y.P., Rubinsztein D.C. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 2002, 277:33791-33798.
17. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A 1998, 95:6480-6485.
18. Choo Y.S., Mao Z., Johnson G.V., Lesort M. Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model. Neurosci Lett 2005, 386:63-68.
19. Chattopadhyay B., Baksi K., Mukhopadhyay S., Bhattacharyya N.P. Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes. Neurosci Lett 2005, 374:81-86.
20. Corrochano S., Renna M., Tomas-Zapico C., Brown S.D., Lucas J.J., Rubinsztein D.C., et al. alpha-Synuclein levels affect autophagosome numbers in vivo and modulate Huntington disease pathology. Autophagy 2012, 8:431-432.
21. Coufal M., Maxwell M.M., Russel D.E., Amore A.M., Altmann S.M., Hollingsworth Z.R., et al. Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments. J Biomol Screen 2007, 12:351-360.
22. del Hoyo P., Garcia-Redondo A., de Bustos F., Molina J.A., Sayed Y., Alonso-Navarro H., et al. Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease. Neurochem Res 2006, 31:1103-1109.
23. Delhanty J.D., Parrington J.M., Casey G., Attwood J., West L., Kirk D., et al. Growth DNA repair, sister chromatid exchange and chromosome studies in fibroblasts from Huntington's disease patients. Ann Hum Genet 1981, 45:181-198.
24. DiFiglia M. Clinical Genetics I.I. Huntington's disease: from the gene to pathophysiology. Am J Psychiatry 1997, 154:1046.
25. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
26. Doumanis J., Wada K., Kino Y., Moore A.W., Nukina N. RNAi screening in Drosophila cells identifies new modifiers of mutant huntingtin aggregation. PLoS ONE 2009, 4:e7275.
27. Dunst S., Kazimiers T., von Zadow F., Jambor H., Sagner A., Brankatschk B., et al. Endogenously tagged rab proteins: a resource to study membrane trafficking in Drosophila. Dev Cell 2015, 33:351-365.
28. Dupont P., Besson M.T., Devaux J., Lievens J.C. Reducing canonical Wingless/Wnt signaling pathway confers protection against mutant Huntingtin toxicity in Drosophila. Neurobiol Dis 2012, 47:237-247.
29. Enokido Y., Tamura T., Ito H., Arumughan A., Komuro A., Shiwaku H., et al. Mutant huntingtin impairs Ku70-mediated DNA repair. J Cell Biol 2010, 189:425-443.
30. Fang Y., Soares L., Bonini N.M. Design and implementation of in vivo imaging of neural injury responses in the adult Drosophila wing. Nat Protoc 2013, 8:810-819.
31. Gafni J., Hermel E., Young J.E., Wellington C.L., Hayden M.R., Ellerby L.M. Inhibition of calpain cleavage of Huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 2004, 279:20211-20220.
32. Gamberino W.C., Brennan W.A. Glucose transporter isoform expression in Huntington's disease brain. J Neurochem 1994, 63:1392-1397.
33. Godin J.D., Poizat G., Hickey M.A., Maschat F., Humbert S. Mutant Huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease. EMBO J 2010, 29:2433-2445.
34. Gray M., Shirasaki D.I., Cepeda C., Andre V.M., Wilburn B., Lu X.H., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 2008, 28:6182-6195.
35. Gray P.N., May P.C., Mundy L., Elkins J. l-Glutamate toxicity in Huntington's disease fibroblasts. Biochem Biophys Res Commun 1980, 95:707-714.
36. Gunawardena S., Her L.S., Brusch R.G., Laymon R.A., Niesman I.R., Gordesky-Gold B., et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003, 40:25-40.
37. Guo J.L., Lee V.M. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 2014, 20:130-138.
38. Gusella J.F., MacDonald M.E. Huntington's disease: the case for genetic modifiers. Genome Med 2009, 1:80.
39. Guzhova I.V., Lazarev V.F., Kaznacheeva A.V., Ippolitova M.V., Muronetz V.I., Kinev A.V., et al. Novel mechanism of Hsp70 chaperone-mediated prevention of polyglutamine aggregates in a cellular model of huntington disease. Hum Mol Genet 2011, 20:3953-3963.
40. Hansson O., Petersen A., Leist M., Nicotera P., Castilho R.F., Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci U S A 1999, 96:8727-8732.
41. Iwata A., Christianson J.C., Bucci M., Ellerby L.M., Nukina N., Forno L.S., et al. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc Natl Acad Sci U S A 2005, 102:13135-13140.
42. Jackson G.R., Salecker I., Dong X., Yao X., Arnheim N., Faber P.W., et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998, 21:633-642.
43. Jeon I., Lee N., Li J.Y., Park I.H., Park K.S., Moon J., et al. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells 2012, 30:2054-2062.
44. Jia H., Pallos J., Jacques V., Lau A., Tang B., Cooper A., et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis 2012, 46:351-361.
45. Jimenez-Sanchez M., Lam W., Hannus M., Sonnichsen B., Imarisio S., Fleming A., et al. siRNA screen identifies QPCT as a druggable target for Huntington's disease. Nat Chem Biol 2015, 11:347-354.
46. Jimenez-Sanchez M., Thomson F., Zavodszky E., Rubinsztein D.C. Autophagy and polyglutamine diseases. Prog Neurobiol 2012, 97:67-82.
47. Kaltenbach L.S., Romero E., Becklin R.R., Chettier R., Bell R., Phansalkar A., et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 2007, 3:e82.
48. Kazemi-Esfarjani P., Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000, 287:1837-1840.
49. Kehoe P., Krawczak M., Harper P.S., Owen M.J., Jones A.L. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet 1999, 36:108-111.
50. Khalil B., El Fissi N., Aouane A., Cabirol-Pol M.J., Rival T., Lievens J.C. PINK1-induced mitophagy promotes neuroprotection in Huntington's disease. Cell Death Dis 2015, 6:e1617.
51. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease with administration of the transglutaminase inhibitor cystamine. Nat Med 2002, 8:143-149.
52. Klevytska A.M., Tebbenkamp A.T., Savonenko A.V., Borchelt D.R. Partial depletion of CREB-binding protein reduces life expectancy in a mouse model of Huntington disease. J Neuropathol Exp Neurol 2010, 69:396-404.
53. Lazzeroni G., Benicchi T., Heitz F., Magnoni L., Diamanti D., Rossini L., et al. A phenotypic screening assay for modulators of huntingtin-induced transcriptional dysregulation. J Biomol Screen 2013, 18:984-996.
54. Lee J., Hong Y.K., Jeon G.S., Hwang Y.J., Kim K.Y., Seong K.H., et al. ATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington's disease. Cell Death Differ 2012, 19:1109-1116.
55. Lee J.H., Tecedor L., Chen Y.H., Monteys A.M., Sowada M.J., Thompson L.M., et al. Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes. Neuron 2015, 85:303-315.
56. Lee T., Luo L. Mosaic analysis with a repressible cell marker (MARCM) for Drosophila neural development. Trends Neurosci 2001, 24:251-254.
57. Lee W.C., Yoshihara M., Littleton J.T. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci U S A 2004, 101:3224-3229.
58. Li X., Sapp E., Chase K., Comer-Tierney L.A., Masso N., Alexander J., et al. Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease. Neurobiol Dis 2009, 36:374-383.
59. Li Z., Karlovich C.A., Fish M.P., Scott M.P., Myers R.M. A putative Drosophila homolog of the Huntington's disease gene. Hum Mol Genet 1999, 8:1807-1815.
60. Lu B., Al-Ramahi I., Valencia A., Wang Q., Berenshteyn F., Yang H., et al. Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance. Nat Neurosci 2013, 16:562-570.
61. Luthi-Carter R., Taylor D.M., Pallos J., Lambert E., Amore A., Parker A., et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA 2010, 107:7927-7932.
62. MacDonald M.E., Vonsattel J.P., Shrinidhi J., Couropmitree N.N., Cupples L.A., Bird E.D., et al. Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology 1999, 53:1330-1332.
63. Maher P., Dargusch R., Bodai L., Gerard P.E., Purcell J.M., Marsh J.L. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet 2011, 20:261-270.
64. Mason R.P., Casu M., Butler N., Breda C., Campesan S., Clapp J., et al. Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. Nat Genet 2013, 45:1249-1254.
65. McClory H., Williams D., Sapp E., Gatune L.W., Wang P., DiFiglia M., et al. Glucose transporter 3 is a rab11-dependent trafficking cargo and its transport to the cell surface is reduced in neurons of CAG140 Huntington's disease mice. Acta Neuropathol Commun 2014, 2:179.
66. McConoughey S.J., Basso M., Niatsetskaya Z.V., Sleiman S.F., Smirnova N.A., Langley B.C., et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med 2010, 2:349-370.
67. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
68. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 2003, 465:11-26.
69. Menzies F.M., Garcia-Arencibia M., Imarisio S., O'Sullivan N.C., Ricketts T., Kent B.A., et al. Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity. Cell Death Differ 2015, 22:433-444.
70. Metzger S., Rong J., Nguyen H.P., Cape A., Tomiuk J., Soehn A.S., et al. Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease. Hum Mol Genet 2008, 17:1137-1146.
71. Michalik A., Van Broeckhoven C. Pathogenesis of polyglutamine disorders: aggregation revisited. Hum Mol Genet 2003, 12(Spec No 2):R173-R186.
72. Miller J.P., Yates B.E., Al-Ramahi I., Berman A.E., Sanhueza M., Kim E., et al. A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease. PLoS Genet 2012, 8:e1003042.
73. Moloney T.C., Hyland R., O'Toole D., Paucard A., Kirik D., O'Doherty A., et al. Heat shock protein 70 reduces alpha-synuclein-induced predegenerative neuronal dystrophy in the alpha-synuclein viral gene transfer rat model of Parkinson's disease. CNS Neurosci Ther 2014, 20:50-58.
74. Naze P., Vuillaume I., Destee A., Pasquier F., Sablonniere B. Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. Neurosci Lett 2002, 328:1-4.
75. Neukomm L.J., Burdett T.C., Gonzalez M.A., Zuchner S., Freeman M.R. Rapid in vivo forward genetic approach for identifying axon death genes in Drosophila. Proc Natl Acad Sci U S A 2014, 111:9965-9970.
76. O'Rourke J.G., Gareau J.R., Ochaba J., Song W., Rasko T., Reverter D., et al. SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell Rep 2013, 4:362-375.
77. Patterson K.R., Ward S.M., Combs B., Voss K., Kanaan N.M., Morfini G., et al. Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry 2011, 50:10300-10310.
78. Pearce M.M., Spartz E.J., Hong W., Luo L., Kopito R.R. Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the Drosophila brain. Nat Commun 2015, 6:6768.
79. Pecho-Vrieseling E., Rieker C., Fuchs S., Bleckmann D., Esposito M.S., Botta P., et al. Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat Neurosci 2014, 17:1064-1072.
80. Pocas G.M., Branco-Santos J., Herrera F., Outeiro T.F., Domingos P.M. alpha-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila. Hum Mol Genet 2015, 24:1898-1907.
81. Power D., Srinivasan S., Gunawardena S. In-vivo evidence for the disruption of Rab11 vesicle transport by loss of huntingtin. Neuroreport 2012, 23:970-977.
82. Richards P., Didszun C., Campesan S., Simpson A., Horley B., Young K.W., et al. Dendritic spine loss and neurodegeneration is rescued by Rab11 in models of Huntington's disease. Cell Death Differ 2011, 18:191-200.
83. Romero E., Cha G.H., Verstreken P., Ly C.V., Hughes R.E., Bellen H.J., et al. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 2008, 57:27-40.
84. Rubinsztein D.C., Leggo J., Chiano M., Dodge A., Norbury G., Rosser E., et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci U S A 1997, 94:3872-3876.
85. Sajjad M.U., Green E.W., Miller-Fleming L., Hands S., Herrera F., Campesan S., et al. DJ-1 modulates aggregation and pathogenesis in models of Huntington's disease. Hum Mol Genet 2014, 23:755-766.
86. Sang T.K., Li C., Liu W., Rodriguez A., Abrams J.M., Zipursky S.L., et al. Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. Hum Mol Genet 2005, 14:357-372.
87. Schulte J., Sepp K.J., Wu C., Hong P., Littleton J.T. High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model. PLoS ONE 2011, 6:e23841.
88. Seo H., Sonntag K.C., Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 2004, 56:319-328.
89. Shiraishi R., Tamura T., Sone M., Okazawa H. Systematic analysis of fly models with multiple drivers reveals different effects of ataxin-1 and huntingtin in neuron subtype-specific expression. PLoS ONE 2014, 9:e116567.
90. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003, 12:1555-1567.
91. Smith G.A., Rocha E.M., McLean J.R., Hayes M.A., Izen S.C., Isacson O., et al. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Hum Mol Genet 2014, 23:4510-4527.
92. Smith M.R., Syed A., Lukacsovich T., Purcell J., Barbaro B.A., Worthge S.A., et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease. Hum Mol Genet 2014, 23:2995-3007.
93. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
94. Steinert J.R., Campesan S., Richards P., Kyriacou C.P., Forsythe I.D., Giorgini F. Rab11 rescues synaptic dysfunction and behavioural deficits in a Drosophila model of Huntington's disease. Hum Mol Genet 2012, 21:2912-2922.
95. Taherzadeh-Fard E., Saft C., Andrich J., Wieczorek S., Arning L. PGC-1alpha as modifier of onset age in Huntington disease. Mol Neurodegener 2009, 4:10.
96. Tamura T., Sone M., Yamashita M., Wanker E.E., Okazawa H. Glial cell lineage expression of mutant ataxin-1 and huntingtin induces developmental and late-onset neuronal pathologies in Drosophila models. PLoS ONE 2009, 4:e4262.
97. Tamura T., Sone M., Iwatsubo T., Tagawa K., Wanker E.E., Okazawa H. Ku70 alleviates neurodegeneration in Drosophila models of Huntington's disease. PLoS ONE 2011, 6:e27408.
98. Thomas E.A., Coppola G., Desplats P.A., Tang B., Soragni E., Burnett R., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 2008, 105:15564-15569.
99. Tian L., Hires S.A., Mao T., Huber D., Chiappe M.E., Chalasani S.H., et al. Imaging neural activity in worms, flies and mice with improved GCaMP calcium indicators. Nat Methods 2009, 6:875-881.
100. Tourette C., Farina F., Vazquez-Manrique R.P., Orfila A.M., Voisin J., Hernandez S., et al. The Wnt receptor Ryk reduces neuronal and cell survival capacity by repressing FOXO activity during the early phases of mutant huntingtin pathogenicity. PLoS Biol 2014, 12:e1001895.
101. Trueman R.C., Brooks S.P., Jones L., Dunnett S.B. Time course of choice reaction time deficits in the Hdh(Q92) knock-in mouse model of Huntington's disease in the operant serial implicit learning task (SILT). Behav Brain Res 2008, 189:317-324.
102. Trueman R.C., Jones L., Dunnett S.B., Brooks S.P. Early onset deficits on the delayed alternation task in the Hdh(Q92) knock-in mouse model of Huntington's disease. Brain Res Bull 2012, 88:156-162.
103. Valencia A., Sapp E., Reeves P.B., Alexander J., Masso N., Li X., et al. Reagents that block neuronal death from Huntington's disease also curb oxidative stress. Neuroreport 2012, 23:10-15.
104. Valencia A., Reeves P.B., Sapp E., Li X., Alexander J., Kegel K.B., et al. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease. J Neurosci Res 2010, 88:179-190.
105. Wang C.T., Chen Y.C., Wang Y.Y., Huang M.H., Yen T.L., Li H., et al. Reduced neuronal expression of ribose-5-phosphate isomerase enhances tolerance to oxidative stress, extends lifespan, and attenuates polyglutamine toxicity in Drosophila. Aging Cell 2012, 11:93-103.
106. Weiss K.R., Kimura Y., Lee W.C., Littleton J.T. Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model. Genetics 2012, 190:581-600.
107. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 2000, 9:503-513.
108. Wu J., Shih H.P., Vigont V., Hrdlicka L., Diggins L., Singh C., et al. Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment. Chem Biol 2011, 18:777-793.
109. Yamamoto S., Jaiswal M., Charng W.L., Gambin T., Karaca E., Mirzaa G., et al. A drosophila genetic resource of mutants to study mechanisms underlying human genetic diseases. Cell 2014, 159:200-214.
110. Yao Y., Cui X., Al-Ramahi I., Sun X., Li B., Hou J., et al. A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity. Elife 2015, 4.
111. Zala D., Hinckelmann M.V., Saudou F. Huntingtin's function in axonal transport is conserved in Drosophila melanogaster. PLoS ONE 2013, 8:e60162.
112. Zhang J., Schulze K.L., Hiesinger P.R., Suyama K., Wang S., Fish M., et al. Thirty-one flavors of Drosophila rab proteins. Genetics 2007, 176:1307-1322.
113. Zhang N., Li B., Al-Ramahi I., Cong X., Held J.M., Kim E., et al. Inhibition of lipid signaling enzyme diacylglycerol kinase epsilon attenuates mutant huntingtin toxicity. J Biol Chem 2012, 287:21204-21213.
114. Zhang S., Binari R., Zhou R., Perrimon N. A genomewide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila. Genetics 2010, 184:1165-1179.
115. Zwilling D., Huang S.Y., Sathyasaikumar K.V., Notarangelo F.M., Guidetti P., Wu H.Q., et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011, 145:863-874.